ACTRIMS 2026 | Relationship between patient-reported outcomes, sociodemographic variables, and EDSS scores in MOGAD
Dalia Rotstein, MD, University of Toronto, Toronto, Canada, discusses a study investigating the relationship between patient-reported outcomes, sociodemographic variables, and EDSS scores in MOGAD. Dr Rotstein reports a high burden of fatigue and pain, which had strong correlations with depression, although no correlations were found in sociodemographic variables or EDSS scores. This interview is part of our coverage of the 11th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We were interested to investigate patient-reported outcomes in MOGAD, specifically as related to fatigue, pain, and mood disorders, such as depression and anxiety. But we have a cohort of people with MOGAD from across Canada through our CANOPTICS study, and we had 61 people who had completed all questionnaires. We used validated questionnaires to assess these symptoms, such as a modified fatigue impact scale and the McGill pain questionnaire...
We were interested to investigate patient-reported outcomes in MOGAD, specifically as related to fatigue, pain, and mood disorders, such as depression and anxiety. But we have a cohort of people with MOGAD from across Canada through our CANOPTICS study, and we had 61 people who had completed all questionnaires. We used validated questionnaires to assess these symptoms, such as a modified fatigue impact scale and the McGill pain questionnaire. And we did find a high burden of these symptoms, particularly of fatigue and pain. Interestingly, we did not find any significant associations with sociodemographic variables, except for there was a slight trend with age, so older patients tended to have a higher burden of these symptoms. We also evaluated for correlations between the individual patient-reported outcomes as well as the EDSS. And we found strong correlations between fatigue and pain and fatigue and depression, but we did not see strong associations with the EDSS. So that was another important point. It seems that the EDSS alone is inadequate to fully characterize the burden of symptoms in people with MOGAD. Although MOGAD is often regarded as a benign disease, our findings suggest that many people do have significant symptoms that are persistent after attacks.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
DLR has received research support from MS Canada, the National MS Society, Canada’s Drug Agency, the Li Ka Shing Knowledge Institute of Unity Health Toronto, University of Toronto Division of Neurology, the Guthy Jackson Foundation, Peter and Susan Gordon, Alexion, and Amgen.
She has received speaking and consulting fees from Alexion, Amgen, Biogen, EMD Serono, Novartis, Roche, and Sanofi.
